Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.
A return to tuck-in deals – sort of.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.